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 Abstract 
 In 1994, in a prospective control trial in cyclosporine-
treated, kidney transplant patients, we observed that 
treatment of a non-specific allograft injury (postisch-
emic reperfusion injury) leads to a significant reduction 
in the incidence of both specific alloimmune-mediated 
allograft rejection and chronic allograft failure. From 
these convincing clinical data, we concluded in terms of 
an ‘argumentum e contrario’: it is the tissue injury that 
induces immunity. As from where we stand today in in-
nate immunity research, these early clinical observations 
can be regarded as the discovery of the existence of a 
human innate immune system activated by tissue injury 
and preceding adaptive immunity. 
 Copyright © 2013 S. Karger AG, Basel 
 Current notions in immunology hold that not 
only pathogen-induced injury but any tissue in-
jury activates the innate immune system leading 
to infectious/sterile tissue inflammation and pre-
ceding adaptive immunity  [1–3] . 
 With respect to these modern notions on a 
fundamental role of the innate immune system in 
inflammation and adaptive immunity, a peer-re-
viewed article that dealt with this issue already at 
an early stage published in  Transplantation in 
1994 appears to be of interest  [4] . In this article, 
we described the existence of a defense system in 
humans (without calling it ‘innate immunity’) 
before first studies on the discovery of the innate 
immune receptor Toll were published  [5, 6] .
 Interestingly enough, our article appeared just 
a few months before Matzinger  [7] published her 
famous danger hypothesis which was remarkably 
in line with our clinical observations.
 These clinical observations derived from a 
prospective, randomized double-blind placebo 
controlled clinical trial that showed a beneficial 
effect of human recombinant superoxide-dis-
mutase (SOD) on acute and chronic rejection 
events in kidney-transplanted patients  [4] .
 The principal design of this clinical study in 
recipients under cyclosporine-based immunosup-
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pression consisted of intravenous administration 
of 200 mg of the free radical scavenger SOD given 
just once during surgery, that is, a few minutes be-
fore renal allograft reperfusion. During the subse-
quent 8-year monitoring phase, SOD-treated pa-
tients revealed a statistically significant reduction 
in the incidence of acute rejection episodes to only 
18% and irreversible graft loss to 3.7%, respective-
ly. The long-term results were also significantly 
improved, and most remarkably the beneficial ef-
fect was even demonstrable 8 years after a single 
injection of SOD ( fig. 1 ). The therapeutic effect ob-
served was dramatic: With regard to the incidence 
of acute rejection episodes under cyclosporine-
based immunosuppression, the administration of 
a single dose of SOD prior to reperfusion is com-
parable to the application of 2 g mycophenolate 
mofetil (MMF) daily, that is, an accumulating 
dose of 730 g MMF within 1 year!
 Thus, these clinical observations indicated 
that treatment of a non-specific allograft injury 
(=postischemic reperfusion injury) results in a 
significant reduction in specific adaptive im-
mune events. From these convincing clinical 
data, we concluded in terms of an ‘argumentum 
e contrario’: tissue injury (here: allograft injury) 
activates a biological immune system that pre-
cedes and activates adaptive immunity (here al-
loimmunity). In the same article  [4] , this conclu-
sion was extended into a working hypothesis,
today known as the Injury Hypothesis. As illus-
trated in  figure 2 , a human immune system in its 
own right was proposed that is activated by non-
pathogen-induced tissue injury (here the post-
ischemic reperfusion injury to a renal allograft, 
that is, a situation where pathogens are obviously 
absent) and that, after activation, leads to the in-
duction of an adaptive immune response (here an 
adaptive alloimmune response resulting in al-
lograft rejection). In the center of this immune 
system, besides others, we proposed a role of an-
tigen-presenting cells (later appreciated to be 
dendritic cells) activated by injury and subse-
quently leading to development of adaptive im-
munity, that is cells operating as a bridge between 
injury and adaptive immunity.
 In addition, in this 1994 article, the possibility 
was discussed that adaptive immune response 
products (cytotoxic T lymphocytes, alloantibod-
ies) induced by this system contribute – via endo-
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 Fig. 1. Clinical data from the Munich 
SOD trial in kidney-transplanted pa-
tients under cyclosporine-based im-
munosuppression. Left: incidence
of acute rejection episodes and irre-
versible graft rejection during the 
first year after transplantation was 
statistically significantly reduced in 
rhSOD-treated recipients (n = 81) 
compared to placebo-treated pa-
tients (n = 96). Right: long-term re-
sults were also significantly im-
proved in rhSOD-treated patients. 
This difference of survival was most 
obvious 4 years after transplanta-
tion, still statistically significant at 6 
years, and still demonstrable at 8 
years although having lost its statis-
tical significance. 
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26  Land  Messmer 
thelial injuries (at that time called ‘allograft en-
dothelitis’) – to chronic allograft dysfunction (at 
that time called chronic obliterative rejection 
vasculopathy).
 In other words, as from where we stand today, 
in 1994, that is before Matzinger published her 
danger model  [7, 8] and before the groups of Hoff-
mann and Beutler published the discovery of Toll 
and TLR4  [5, 6] , we had discovered the existence of 
a human innate immune system activated by tissue 
injury and preceding adaptive immunity. We only 
missed to call it  innate immunity . However, 2 years 
later, in 1996, in a review article, at least we briefly 
addressed this system as ‘natural immunity’  [9] .
 Our Injury Hypothesis – based on statistically 
significant clinical data – together with Matzing-
er’s Danger Hypothesis – proposed entirely on 
theoretical grounds – could now extend the con-
ceptual framework of the late Charles Janeway 
proposing that the immune system did not re-
spond to all foreign antigens but only to those 
that are potentially associated with infection. 
Janeway’s underlying idea was that the immune 
system evolved to discriminate infectious non-
self from non-infectious self  [10, 11] . In fact, Jane-
way’s hypothesis turned out to be too simplistic. 
Most importantly, however, his model could not 
explain all immune responses, in particular, not 
the robust T cell-mediated alloimmune response 
leading to allograft rejection, a process in the ap-
parent absence of microbial infection.
 In fact, the danger/injury model can now ex-
plain why the innate immune system is able to 
mount an efficient immune response against 
harmful injurious pathogenic microorganisms, 
but not against harmless non-pathogenic micro-
organisms: it is the presentation of microbial
antigens in the context of pathogen-induced tis-
sue injury that triggers an efficient immune re-
sponse – not simply the foreignness of microbial 
antigens. Likewise, the danger/injury model can 
also explain why the innate immune system 
sometimes mounts an efficient immune response 
against non-self foreign tissue such as transplant-
ed alloantigens, but sometimes not, for example 
in case of fetal semi-alloantigens  [12] . The answer 
is: the system distinguishes between an injured 
transplant (rejection) and a non-injured fetus 
(tolerance). Again, it is the presentation of alloan-
tigens in the context of tissue injury that triggers 
an efficient alloimmune response, and not simply 
the foreignness of allogeneic tissue as reflected, 
for example, by an HLA-mismatch.
 After the rediscovery of the innate immunity 
system, as published in first reports during the 
late 1990s/early 2000s, a concept of the potential 
impact of the innate immune events on allograft 
rejection was introduced by review articles to the 
Ischemia
Reperfusion injury
Increased immunogenicity
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Increased incidence of acute rejection episodes
Early graft loss
Upregulation (?) of
(1) DR expression,
(2) adhesion Ag expression,
(3) phagocytosis
(APC reactivity)
 Fig. 2. This figure is traced, redrawn, and modified from 
figure 2 of the original 1994 article  [4] . We proposed a hu-
man immune system in its own right that is activated by 
non-pathogen-induced tissue injury (here the postisch-
emic reperfusion injury to a renal allograft) and that, after 
activation, leads to the induction of an adaptive immune 
response (here an adaptive alloimmune response result-
ing in allograft rejection). In the center of this immune 
system (apart from others), we proposed a role of anti-
gen-presenting cells activated by injury and subsequent-
ly leading to the development of adaptive immunity. 
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transplant community in 2002/2003 for the first 
time  [13–16] . In these reviews, in a subsequent ar-
ticle  [17] as well as in a recently published mono-
graph  [18] , the original Injury Hypothesis was ex-
tended and modified several times. Along with 
these modifications, we coined the terms ‘innate 
alloimmunity’ in 2002  [13] and ‘damage-associ-
ated molecular patterns’ (DAMPs) in 2003  [16] . 
Moreover, in 2003, we predicted that TLR4 medi-
ates reperfusion injury-induced inflammatory 
response, a prediction that was confirmed only 1 
year later by data of the group of Kupiec-Weglin-
ski at UCLA showing that TLR4 activation medi-
ates liver ischemia/reperfusion inflammatory re-
sponse  [19] .
 In particular, in these review articles, we pro-
posed that oxidative stress to the brain-dead do-
nor organism as well as the generation of reactive 
oxygen species during reperfusion of the al-
lograft represent acute injurious events to the do-
nor organ that, in turn, lead to acute rejection. By 
activation of donor/recipient PRR-bearing den-
dritic cells of the innate immune system via inter-
action of DAMPs with Toll-like receptors, these 
events lead to initiation of adaptive alloimmuni-
ty  [17] .
 In our last published review article, evidence 
is provided in support of the notion that preven-
tion of oxidative allograft injury may operate as 
an efficient tool in the clinical situation to present 
alloantigens under subimmunogenic conditions 
within an intragraft non-inflammatory milieu, 
thereby potentially generating tolerogenic den-
dritic cells able to induce Foxp3+ regulatory T 
cell-mediated innate allotolerance  [20] – in fact 
an allotolerance-inducing principle that has been 
proven to be successful in elegant experiments in 
mice by Verginis et al.  [21] . Indeed, such a con-
cept may be discussed in view of our early clinical 
observation that the effect of a single intravenous 
injection of SOD to transplant patients is demon-
strable even 8 years after its application – indicat-
ing that this free radical scavenger must have
induced a fundamental long-lasting active sup-
pressive process.
 Although in earlier times heavily opposed and 
later on notoriously neglected by the transplant 
community, our Injury Hypothesis has just re-
cently gained center stage and obviously appears 
well accepted by leading transplant immunolo-
gists  [22, 23] . Time seems now to be ripe to think 
of new immunosuppressive strategies in organ 
transplantation such as interfering with the do-
nor’s innate immune system during organ re-
moval and the recipient’s innate immune system 
during allograft reperfusion, for example with 
the use of antioxidants, anti-IL-1  inhibitors,
anticomplement agents, and polyclonal antilym-
phocyte preparations.
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